A phase II study of weekly docetaxel plu
β
Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C
π
Article
π
2003
π
John Wiley and Sons
π
English
β 86 KB
π 2 views
## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmallβcell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch